Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma: a cost-effectiveness analysis

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
17386043

DOI
10.1111/j.1525-1438.2007.00915.x

Indexing Status
Subject indexing assigned by NLM

MeSH
Antineoplastic Agents /adverse effects /therapeutic use; Bridged Compounds /adverse effects /therapeutic use; Carcinoma /drug therapy; Cohort Studies; Cost-Benefit Analysis; Female; Filgrastim; Granulocyte Colony-Stimulating Factor /economics /therapeutic use; Hospitalization /economics; Humans; Neutropenia /etiology /prevention & control; Ovarian Neoplasms /drug therapy; Recombinant Proteins; Taxoids /adverse effects /therapeutic use

AccessionNumber
22007001992

Date bibliographic record published
08/10/2007